- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07799610
Senior Center Medication Safety and Empowerment Curriculum
27. august 2026 oppdatert av: Robert Wahler, State University of New York at Buffalo
Team Alice Senior Center Medication Safety and Empowerment Curriculum
Team Alice's Medication Safety and Empowerment Curriculum (MedSEC) helps older adults and caregivers learn how to safely manage medications.
Many seniors take multiple medications, which can lead to harmful side effects or unnecessary treatments.
This program, developed at the University at Buffalo, will be offered at senior centers in Western New York.
It includes two interactive sessions that teach participants how to recognize medication risks and talk with their doctors about safer options.
The curriculum uses videos, group discussions, and hands-on tools to build confidence and knowledge.
It follows the "4Ms" of Age-Friendly Health Systems: What Matters, Medication, Mentation, and Mobility.
A "Train-the-Trainer" model will help senior center staff continue the program long-term.
The goal is to reduce medication harm, improve communication with healthcare providers, and support healthy aging in the community.
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
125
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
New York
-
Buffalo, New York, Forente stater, 142148033
- Rekruttering
- University at Buffalo
-
Ta kontakt med:
- Robert G Wahler, Doctor of Pharmacy
- Telefonnummer: 7166454777
- E-post: rgwahler@buffalo.edu
-
Hovedetterforsker:
- Robert G Wahler, Doctor of Pharmacy
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- 55 years of age and above
- taking prescription medications
Carepartner Inclusion Criteria:
- currently an informal or formal care partner for an eligible patient (regardless of whether they live with or near the patient)
- aged 18 years of age and above
Exclusion Criteria:
- Patients with cognitive impairment that prevents their self-management of medications.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluate the impact of the MedSEC on patient/care-partner knowledge and activation levels in managing medications through the Patient Activation Measure (PAM)
Tidsramme: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
Study seeks to enhance patient and care-partner activation, reduce polypharmacy and the use of potentially inappropriate medications (PIMs), and improve shared decision-making through the Patient Activation Measure (PAM).
|
Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
|
Evaluate the impact of the MedSEC on patient/care-partner knowledge and activation levels in managing medications through the Revised Patient Attitudes Towards Deprescribing (rPATD) questionnaires.
Tidsramme: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
Study seeks to enhance patient and care-partner activation, reduce polypharmacy and the use of potentially inappropriate medications (PIMs), and improve shared decision-making through the Revised Patient Attitudes Towards Deprescirbing (rPATD) questionnaires.
|
Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in participant understanding of medication safety risks at 6 Months.
Tidsramme: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
85% of participants will demonstrate an understanding of medication safety risks through pre- and post-program patient/caregiver questionnaires, including the Patient Activation Measure (PAM) and Revised Patient Attitudes to Deprescribing (rPATD).
Additional questions pertaining to knowledge retention and actionability will be asked at 6 months.
|
Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
|
Participants will demonstrate knowledge of the 4Ms (Age-Friendly Health System) framework through pre/post/6 month follow up questionnaires.
Tidsramme: Change from baseline, post-program assessment (immediately after program completion), and 6 months after program completion.
|
By the end of the program, 80% of participants will demonstate knowledge of the 4Ms framework, measured by four questions related to the 4Ms and the Age-Friendly Health System taken prior to the program, immediately post-program, and 6 months after program completion.
|
Change from baseline, post-program assessment (immediately after program completion), and 6 months after program completion.
|
|
Change in patient engagement as measured by the Patient Activation Measure (PAM) from baseline to 6 months post program.
Tidsramme: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
6 months post-program, 65% of participants will show improved patient engagement, as measured by the Patient Activation Measure (PAM) questionnaire.
|
Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
|
|
Change from baseline in the mean of medications after 6 months follow-up
Tidsramme: Change from baseline and 6 months after program completion.
|
Within 6 months of completing program, 50% of participants with polypharmacy will have reduced medication usage by 10%.
(mean # of medications.)
|
Change from baseline and 6 months after program completion.
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Post-Survey to Measure Program Impact and Participant Satisfaction
Tidsramme: Post curriculum session 2 (immediately after educational session 2, Day 7)
|
A post-survey questionnaire (immediately after program completion) will be used to assess the program's educational value and determine its effectiveness in increasing medication safety knowledge, empowerment, and patient self-advocacy, as well as participant satisfaction.
|
Post curriculum session 2 (immediately after educational session 2, Day 7)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. februar 2026
Primær fullføring (Antatt)
1. februar 2027
Studiet fullført (Antatt)
31. mars 2027
Datoer for studieregistrering
Først innsendt
21. november 2025
Først innsendt som oppfylte QC-kriteriene
27. august 2026
Først lagt ut (Faktiske)
2. september 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
2. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
27. august 2026
Sist bekreftet
1. august 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- STUDY00009882
- G-202509-02155 (Annet stipend/finansieringsnummer: Health Foundation for Western & Central New York)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .